|Podcasts|April 25, 2019

Episode 30: Challenges in Renal Disease Drug Development

Author(s)Lisa Henderson, Christen Harm

Pharm Exec editors interview Anna Sundgren, the renal disease strategy leader, Global Medicines Development at AstraZeneca, about the current CVRM landscape, challenges to renal drug development, and new therapeutics for chronic kidney disease.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

September 18th, 2026

Pharmaceutical Executive Daily: FDA Approves Fayuvi

FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.

September 17th, 2026

Pharmaceutical Executive Daily: FDA Approves New Indication for Kerendia

FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.

September 16th, 2026

Pharmaceutical Executive Daily: Novo Partners with Anthropic

Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reimagining medical content as a loop rather than a pipeline.

September 15th, 2026

Pharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic Partnership

GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.

September 14th, 2026

Pharmaceutical Executive Daily: Novo Nordisk Enters Rebrand

Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in obesity and diabetes care, and Wendy Short Bartie of Bristol Myers Squibb makes the case for reputation as a strategic currency.

September 11th, 2026

Pharmaceutical Executive Daily: Novartis Shareholders Raise Concerns over M&A Strategy

Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan argues health care needs an orchestration layer rather than more point solutions, and Nacho Quinones and Aisling O'Loughlin make the case for synthetic advisory boards in biopharma decision-making.

Episode 30: Challenges in Renal Disease Drug Development

Related to this article

Trending on PharmExec

FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A

M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz

Why Executive MFN Deals Aren't Enough: Q&A with Joe Cunningham

Pharmaceutical Executive Daily: FDA Approves Fayuvi

Understanding the Latest with MFN Pricing and What It Means to Pharma